Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: PaulW who wrote (3768)	10/13/1999 3:43:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Thanks, Paul. For an ICE, the calculation is of course more complex. If the ICE can be released while the original is still on patent, and pricing is comparable, then managed care should have no reason to not pay for the "improved" drug. There of course will not be direct substitution with a generic, but offsetting this is that the brand name parent drug will (albeit illogically) probably retain some market share. If the ICE is released when the generics are already out, then getting reimbursement will be harder unless there is a convincing improvement over the original. On another issue, here's an interesting release from Skye on Novartis' formoterol: Message 11533623 (Skye is also SEPR's partner on MDI Xopenex). Peter